Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sulfo-tanshinone sodium
- Development stage
- Phase 4
- Lead developer
- SPH No. 1 Biochemical & Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intramuscular, Intravenous, Parenteral
01
Overview
sulfo-tanshinone sodium (also known as sodium tanshinone IIA sulfonate) is a water-soluble sulfonated derivative of tanshinone IIA, a major lipophilic diterpenoid quinone extracted from the traditional Chinese medicinal herb Salvia miltiorrhiza (Danshen). Developed by SPH No. 1 Biochemical & Pharmaceutical, it is approved in China for the treatment of cardiovascular diseases, including coronary heart disease, angina pectoris, and myocardial infarction. The drug exhibits multi-targeted pharmacological activities, including anti-inflammatory, antioxidant, anti-apoptotic, and anticoagulant effects. It acts as a negative allosteric modulator of the purinergic receptor P2X7, inhibits store-operated calcium entry (SOCE) through store-operated calcium channels (SOCC) by downregulating transient receptor potential canonical (TRPC) proteins, and modulates various transcription factors such as NF-κB and Nrf2. It is administered via injection (intramuscular, intravenous, or intravenous infusion).
- Brand names
- Nuoxinkang
- Other names
- STSTIIASsodium tanshinone II-A sulfonatesodium tanshinone IIA sulfonatesulfotanshinone sodiumsulfotanshinone sodium II-Atanshinone IIA sodium sulfonatetanshinone IIA sulfonate sodium丹参酮IIA磺酸钠丹参酮IIA磺酸钠注射液丹参酮ⅡA磺酸钠丹参酮ⅡA磺酸钠注射液
02
Targets
P2RX7 (P2X purinoceptor 7)SIRT1 (NAD-dependent protein deacetylase sirtuin-1)KCNMA1 (Calcium-activated potassium channel subfamily M alpha member 1)
Beyond the preview
Go deeper on sulfo-tanshinone sodium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sulfo-tanshinone sodium.